The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A Rating Scale for Drug-Induced Akathisia
Abstract
A rating scale for drug-induced akathisia has been derived that incorporates diagnostic criteria for pseudoakathisia, and mild, moderate, and severe akathisia. It comprises items for rating the observable, restless movements which characterise the condition, the subjective awareness of restlessness, and any distress associated with the akathisia. In addition, there is an item for rating global severity. A standard examination procedure is recommended. The inter-rater reliability for the scale items (Cohen's x) ranged from 0.738 to 0.955. Akathisia was found in eight of 42 schizophrenic inpatients, and nine had pseudoakathisia, where the typical sense of inner restlessness was not reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Survey of Drug-Induced Extrapyramidal Reactions
Ayd, F. J. (1961) · JAMA · doi:10.1001/jama.1961.03040120016004 · Cited by 753
Why Do Schizophrenic Patients Refuse to Take Their Drugs?
Van Putten, T. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760130049008 · Cited by 572
The Leeds Scales for the Self-Assessment of Anxiety and Depression
Snaith, R. P., Bridge, G. W. K., & Hamilton, M. (1976) · British Journal of Psychiatry · doi:10.1192/bjp.128.2.156 · Cited by 280
Akathisia Variants and Tardive Dyskinesia
Barnes, T. R. E. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790320042006 · Cited by 255
Self-citationBraude, W. M., Barnes, T. R. E., & Gore, S. M. (1983) · British Journal of Psychiatry · doi:10.1192/bjp.143.2.139 · Cited by 249
Self-citationVan Putten, T. (1975) · Comprehensive Psychiatry · doi:10.1016/0010-440x(75)90019-x · Cited by 230
Suicide attempts associated with akathisia
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.499 · Cited by 201
Akathisia With Haloperidol and Thiothixene
Putten, T. V. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220026004 · Cited by 160
Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study
Weiden, P. J., Mann, J. J., Haas, G. L., Mattson, M., & FRANCES, A. J. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1148 · Cited by 147
Cited by
Items 101–185 of 185
Macfadden, W., Alphs, L., Haskins, J. T., Turner, N., Turkoz, I., Bossie, C., Kujawa, M., & Mahmoud, R. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00761.x · Cited by 178
Anxiety in Patients with Schizophrenia: Epidemiology and Management
Temmingh, H., & Stein, D. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0282-7 · Cited by 173
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Grossberg, G. T., Kohegyi, E., Mergel, V., Josiassen, M. K., Meulien, D., Hobart, M., Slomkowski, M., Baker, R. A., McQuade, R. D., & Cummings, J. L. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.09.009 · Cited by 169
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162
Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients.
Janno, S., Holi, M., Tuisku, K., & Wahlbeck, K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.160 · Cited by 152
1H-MRS at 4 Tesla in minimally treated early schizophrenia
Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y. C., et al. (2010) · BMJ · doi:10.1136/bmj.c4024 · Cited by 151
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
Zarate, C. A., & Tohen, M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.169 · Cited by 144
Baynes, D., Mulholland, C., Cooper, S. J., Montgomery, R. C., MacFlynn, G., Lynch, G., Kelly, C., & King, D. J. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00205-4 · Cited by 136
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., Perry, P., Hertel, P., Such, P., Salzman, P. M., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11201 · Cited by 135
Dysfunctional neural plasticity in patients with schizophrenia
Daskalakis, Z. J., Christensen, B. K., Fitzgerald, P. B., & Chen, R. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.378 · Cited by 130
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
Lee, D., Slomkowski, M., Hefting, N., Chen, D., Larsen, K. G., Kohegyi, E., Hobart, M., Cummings, J. L., & Grossberg, G. T. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3810 · Cited by 135
Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects
Åberg, K., Adkins, D. E., Bukszár, J., Webb, B. T., Caroff, S. N., Miller, D. D., Sebat, J., Stroup, S., Fanous, A. H., Vladimirov, V. I., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.036 · Cited by 130
Sachs, G. S., Greenberg, W. M., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Németh, G., & Durgam, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.018 · Cited by 127
Kane, J. M., Cohen, M., Zhao, J., Alphs, L., & Panagides, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d35d6b · Cited by 126
Findling, R. L., Correll, C. U., Nyilas, M., Forbes, R. A., McQuade, R. D., Jin, N., Ivanova, S., Mankoski, R., Carson, W. H., & Carlson, G. A. (2013) · Bipolar Disorders · doi:10.1111/bdi.12042 · Cited by 121
Czobor, P., Van Dorn, R. A., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Volavka, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.003 · Cited by 112
Halstead, S. M., Barnes, T. R. E., & Speller, J. C. (1994) · British Journal of Psychiatry · doi:10.1192/bjp.164.2.177 · Cited by 108
Self-citationBerwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.047 · Cited by 101
Sivrioglu, E. Y., Kirli, S., Sipahioglu, D., Gursoy, B., & Sarandöl, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.004 · Cited by 102
Sarró, S. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00490-5 · Cited by 101
Findling, R. L., Johnson, J. L., McClellan, J., Frazier, J. A., Vitiello, B., Hamer, R. M., Lieberman, J. A., Ritz, L., McNamara, N. K., Lingler, J., et al. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.03.013 · Cited by 101
The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing
Vila-Rodriguez, F., Panenka, W. J., Lang, D. J., Thornton, A. E., Vertinsky, T., Wong, H., Barr, A. M., Procyshyn, R. M., Sidhu, J. J., Smith, G. N., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12111439 · Cited by 94
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180691779 · Cited by 90
The Assessment and Treatment of Antipsychotic-Induced Akathisia
Pringsheim, T., Gardner, D., Addington, D., Martino, D., Morgante, F., Ricciardi, L., Poole, N., Remington, G., Edwards, M., Carson, A., et al. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718760288 · Cited by 89
Self-citationFleischhacker, W. W., Hobart, M., Ouyang, J., Forbes, A., Pfister, S., McQuade, R. D., Carson, W. H., Sanchez, R., Nyilas, M., & Weiller, E. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw076 · Cited by 88
Ravenstijn, P., Remmerie, B., Savitz, A., Samtani, M. N., Nuamah, I., Chang, C., De Meulder, M., Hough, D., & Gopal, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.597 · Cited by 86
Flint, A. J., Meyers, B. S., Rothschild, A. J., Whyte, E. M., Alexopoulos, G. S., Rudorfer, M. V., Marino, P., Banerjee, S., Pollari, C. D., Wu, Y., et al. (2019) · JAMA · doi:10.1001/jama.2019.10517 · Cited by 85
Nicol, G. E., Yingling, M. D., Flavin, K. S., Schweiger, J. A., Patterson, B. W., Schechtman, K. B., & Newcomer, J. W. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1088 · Cited by 83
Dextromethorphan abuse: Clinical effects and management
Romanelli, F., & Smith, K. M. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.08091 · Cited by 77
Wichniak, A., Skowerska, A., Chojnacka-Wójtowicz, J., Tafliński, T., Wierzbicka, A., Jernajczyk, W., & Jarema, M. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.05.009 · Cited by 75
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000123 · Cited by 74
Suppes, T., Hirschfeld, R. M., Vieta, E., Raines, S., & Paulsson, B. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701317265 · Cited by 73
Quetiapine for the treatment of bipolar mania in older adults
Sajatovic, M., Calabrese, J. R., & Mullen, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00614.x · Cited by 70
Stedman, M., Pettinati, H. M., Brown, E. S., Kotz, M., Calabrese, J. R., & Raines, S. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01270.x · Cited by 70
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety
Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69
Suppes, T., Kroger, H., Pikalov, A., & Loebel, A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.012 · Cited by 65
Carlson, B. X., Ketter, T. A., Sun, W., Timko, K., McQuade, R. D., Sanchez, R., Vester‐Blokland, E., & Marcus, R. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00974.x · Cited by 63
Poyurovsky, M., Epshtein, S., Fuchs, C., Schneidman, M., Weizman, R., & Weizman, A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084027.22282.16 · Cited by 62
Coppola, D., Liu, Y., Gopal, S., Remmerie, B., Samtani, M. N., Hough, D. W., Nuamah, I., Sulaiman, A., & Pandina, G. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-26 · Cited by 61
“At endpoint, overall rates were: 1%, akathisia (n = 3; based on BARS clinical rating); 2%, dyskinesia (n = 5; based on AIMS score); and 16%, parkinsonism (n = 34/212; based on SAS global score) (Treatment A [16%; n = 29/186]; Treatment B [19%; n = 5/26]).”
MethodPotential effectiveness and safety of olanzapine in refractory panic disorder
Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005) · Depression and Anxiety · doi:10.1002/da.20050 · Cited by 58
Calabrese, J. R., Pikalov, A., Streicher, C., Cucchiaro, J., Mao, Y., & Loebel, A. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.013 · Cited by 55
Forbes, A., Hobart, M., Ouyang, J., Shi, L., Pfister, S., & Hakala, M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy002 · Cited by 52
Brown, E. S., Davila, D., Nakamura, A., Carmody, T. J., Rush, A. J., Lo, A., Holmes, T., Adinoff, B., Caetano, R., Swann, A. C., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12445 · Cited by 50
Sajatovic, M., Gildengers, A., Al Jurdi, R. K., Gyulai, L., Cassidy, K. A., Greenberg, R. L., Bruce, M. L., Mulsant, B. H., Ten Have, T., & Young, R. C. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00923.x · Cited by 49
Cleton, A., Rossenu, S., Crauwels, H., Berwaerts, J., Hough, D., Gopal, S., Eerdekens, M., Vandebosch, A., Remmerie, B., De Meulder, M., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.295 · Cited by 48
Berna, F., Misdrahi, D., Boyer, L., Aouizerate, B., Brunel, L., Capdevielle, D., Chereau, I., Danion, J. M., Dorey, J. M., Dubertret, C., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.040 · Cited by 47
Determining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen, P., Emsley, R. A., Turner, J., & Keyter, N. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500403 · Cited by 48
Correll, C. U., Cucchiaro, J., Silva, R., Hsu, J., Pikalov, A., & Loebel, A. (2016) · CNS Spectrums · doi:10.1017/s1092852915000917 · Cited by 48
Miodownik, C., Lerner, V., Statsenko, N., Dwolatzky, T., Nemets, B., Berzak, E., & Bergman, J. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200603000-00002 · Cited by 47
Kim, S.-W., Shin, I.-S., Kim, J.-M., Lee, J.-H., Lee, Y.-H., Yang, S.-J., & Yoon, J.-S. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31819a68b5 · Cited by 47
Young, A. H., McElroy, S. L., Olausson, B., Paulsson, B., (D1447C00001), O. B. O. T. E. I., & Embolden II (D1447C00134) Investigators (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.665177 · Cited by 46
Lerner, V., Bergman, J., Statsenko, N., & Miodownik, C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1118 · Cited by 44
Vieta, E., Thase, M. E., Naber, D., D’Souza, B., Rancans, E., Lepola, U., Olausson, B., Szamosi, J., Wilson, E., Hosford, D., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.008 · Cited by 43
Sheehan, D. V., Harnett-Sheehan, K., Hidalgo, R. B., Janavs, J., McElroy, S. L., Amado, D., & Suppes, T. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.016 · Cited by 42
Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers
Handley, R., Mondelli, V., Zelaya, F., Marques, T., Taylor, H., Reinders, A. A. T. S., Chaddock, C., McQueen, G., Hubbard, K., Papadopoulos, A., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.039 · Cited by 42
“Clinical side effects, measured using the Barnes Akathisia scale (Barnes, 1989), the Simpson Angus scale (Simpson and Angus, 1970), and the Abnormal Involuntary Movement Scale (AIMS: National Institute of Mental Health), were evaluated 3 hours post intervention.”
MethodReward-driven decision-making impairments in schizophrenia
Saperia, S., Da Silva, S., Siddiqui, I., Agid, O., Daskalakis, Z. J., Ravindran, A., Voineskos, A. N., Zakzanis, K. K., Remington, G., & Foussias, G. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2018.11.004 · Cited by 41
Matsui, K., Tokumasu, T., Takekita, Y., Inada, K., Kanazawa, T., Kishimoto, T., Takasu, S., Tani, H., Tarutani, S., Hashimoto, N., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.030 · Cited by 41
Ishigooka, J., Iwashita, S., Higashi, K., Liew, E. L., & Tadori, Y. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.979 · Cited by 38
Bourin, M. S., Severus, E., Schronen, J. P., Gass, P., Szamosi, J., Eriksson, H., & Chandrashekar, H. (2014) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0014-9 · Cited by 40
Raoufinia, A., Peters-Strickland, T., Nylander, A.-G., Baker, R. A., Eramo, A., Jin, N., Bricmont, P., Repella, J., McQuade, R. D., Hertel, P., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw116 · Cited by 39
Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis
Takeuchi, H., MacKenzie, N. E., Samaroo, D., Agid, O., Remington, G., & Leucht, S. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa063 · Cited by 39
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Modestin, J., Wehrli, M. V., Stephan, P. L., & Agarwalla, P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.018 · Cited by 38
Vieta, E., Suppes, T., Ekholm, B., Udd, M., & Gustafsson, U. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.014 · Cited by 37
Chung, M.-S., Yang, A. C., Lin, Y.-C., Lin, C.-N., Chang, F.-R., Shen, S.-H., Ouyang, W.-C., Loh, E.-W., & Chiu, H.-J. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.07.034 · Cited by 34
Avital, A., Gross-Isseroff, R., Stryjer, R., Hermesh, H., Weizman, A., & Shiloh, R. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.02.006 · Cited by 33
Chen, X.-J., Liu, L.-L., Cui, J.-F., Wang, Y., Chen, A.-T., Li, F.-H., Wang, W.-H., Zheng, H.-F., Gan, M.-Y., Li, C.-Q., et al. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.01121 · Cited by 34
Malla, A., Chue, P., Jordan, G., Stip, E., Koczerginski, D., Milliken, H., Joseph, A., Williams, R., Adams, B., Manchanda, R., et al. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.mach.061213 · Cited by 30
High-Dose Olanzapine for Treatment-Refractory Schizophrenia
Lerner, V. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200303000-00003 · Cited by 29
Wang, D., Schneider-Thoma, J., Siafis, S., Burschinski, A., Dong, S., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad089 · Cited by 29
McElroy, S. L., Martens, B. E., Winstanley, E. L., Creech, R., Malhotra, S., & Keck (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.11.014 · Cited by 27
Rossenu, S., Cleton, A., Hough, D., Crauwels, H., Vandebosch, A., Berwaerts, J., Eerdekens, M., Herben, V., De Meulder, M., Remmerie, B., et al. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.144 · Cited by 26
Weisler, R. H., Khan, A., Trivedi, M. H., Yang, H., Eudicone, J. M., Pikalov, A., Tran, Q. V., Berman, R. M., & Carlson, B. X. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05495gre · Cited by 19
Ozawa, C., Bies, R. R., Pillai, N., Suzuki, T., Mimura, M., & Uchida, H. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001046 · Cited by 18
Akathisia: a life-threatening side effect of a common medication
Cheng, H. M., Park, J. H., & Hernstadt, D. (2013) · BMJ Case Reports · doi:10.1136/bcr-2012-007713 · Cited by 16
Politis, A. M., Papadimitriou, G. N., Theleritis, C. G., Psarros, C., & Soldatos, C. R. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.011 · Cited by 15
Lepola, U., Hefting, N., Zhang, D., & Hobart, M. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4952 · Cited by 15
Tsuboi, T., Suzuki, T., Bies, R. R., Remington, G., Pollock, B. G., Mimura, M., & Uchida, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.03.025 · Cited by 13
Li, X., Chu, M.-Y., Lv, Q.-Y., Hu, H.-X., Li, Z., Yi, Z.-H., Wang, J.-H., Zhang, J.-Y., Lui, S. S. Y., Cheung, E. F. C., et al. (2019) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2019.1674644 · Cited by 12
Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis
Takeuchi, H., Thiyanavadivel, S., Agid, O., & Remington, G. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.011 · Cited by 12
Mittal, D., Owen, R., Lacro, J., Landes, R., Edlund, M., Valenstein, M., & Jeste, D. (2009) · European Psychiatry · doi:10.1016/s0924-9338(09)71404-x · Cited by 4
Metadata
- Authors
- Barnes, T. R. E.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1989-05
- Volume
- 154
- Issue
- 5
- Pages
- 672-676
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1999689270
- Cited by
- 2,170
- References
- 25
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.